secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001193125-24-200684
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio prices public offering of 2.75M shares at $36.50 for ~$100M gross
----------------------------------------------------------------------------

- Gross proceeds ~$100M from sale of 2,750,498 shares at $36.50 per share.
- Net proceeds to fund general corporate purposes including Phase III readiness of ANB032 and rosnilimab.
- Offering expected to close on August 15, 2024, subject to customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000119312524200684/0001193125-24-200684-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000119312524200684/d874118d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-200684

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer